Study of a Galenic Immunonutrition Supplement in Adults with Head and Neck, Lung, or Rectal Cancer Receiving Cancer Treatments

What this Trial Is About

Researchers are evaluating the effects of a galenic immunonutrition dietary supplement in adults with head and neck squamous cell carcinoma, locally advanced rectal cancer, or lung cancer who are undergoing standard cancer treatments like chemoradiotherapy, chemotherapy, radiotherapy, or immunotherapy. This phase II interventional study aims to see if the supplement can reduce treatment-related side effects and improve how well patients stick to their treatment plans, comparing results to a previous observational study group. Participants will take a specially formulated galenic immunonutrition jelly twice daily starting on the first day of their cancer treatment and continue for up to 45 days. Alongside this supplement, they will receive standard nutritional counseling and routine cancer care. The study is single-arm and conducted at a single center, focusing on how the supplement works as part of their ongoing treatment. During the study, participants will be closely monitored for treatment-related side effects, nutritional status, body composition, muscle function, immune system markers, quality of life, physical activity, and how well they tolerate both the cancer treatment and the supplement. Researchers will measure various health and treatment adherence outcomes up to 63 days from the start of treatment, including detailed blood tests and assessments of physical strength and performance. The overall participation may last up to about two months, with safety and treatment compliance carefully tracked.

Galenos 2 Immunonutrition in Head and Neck, Lung, and Rectal Cancer Patients